<doc>
  <docmeta id="113hr4592ih">
    <bill congress="113" type="hr" number="4592" version="ih"/>
    <revision size="21065" annotations="0" status="complete" id="10" commit-time="2014-06-25T20:59:03Z" committer="mbohmer" doc="113hr4592ih/10.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H80D6ED2C7FA740D2ACC8027706E69C58" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 4592 IH: Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2014</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-05-07</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 4592</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20140507">May 7, 2014</action-date>
			<action-desc>
        <sponsor name-id="G000549">Mr. Gerlach</sponsor> (for himself and <cosponsor name-id="H001047">Mr. Himes</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Public Health Service Act to improve the diagnosis and treatment of hereditary
			 hemorrhagic telangiectasia, and for other purposes.</official-title>
	</form>
	<legis-body id="H0837E639E8874B40993A0DB8A86B7A49" style="OLC">
		<section id="HCD2ED1A1984D4A3DABF0F93AB224E135" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the <quote>
          <short-title>
            <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2014" proposed="true">Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2014</cato:entity-ref>
          </short-title>
        </quote>.</text>
		</section>
    <section id="H0E934656BD6048C59DCE9DA92B8B2AEB">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> finds as follows:</text>
			<paragraph id="HB626B49334E54240A468CCF389C291AA">
        <enum>(1)</enum>
        <text>Hereditary hemorrhagic telangiectasia (HHT) is a largely undiagnosed or misdiagnosed vascular
			 genetic bleeding disorder resulting in artery-vein malformations (AVMs)
			 which lead to preventable catastrophic and disabling consequences. HHT can
			 cause sudden death at any age, unless detected and treated. Early
			 detection, screening, and use of readily available treatment can prevent
			 premature deaths and long-term health complications resulting from HHT. A
			 person with HHT has the tendency to form blood vessels that lack the
			 capillaries between an artery and vein. HHT often results in spontaneous
			 hemorrhage or stroke from brain or lung AVM. In addition to hemorrhagic
			 stroke, embolic stroke and brain abscess occur in approximately 30 percent
			 of persons with HHT artery-vein malformations in the lung (due to lack of
			 capillaries between the arterial and venous systems which normally filter
			 out clots and bacteria).</text>
			</paragraph>
      <paragraph id="HD3BD7AFEFA9B4E62A871365A4BEB0711">
        <enum>(2)</enum>
        <text>One in 5,000 American children and adults suffer from HHT.</text>
			</paragraph>
      <paragraph id="H553F71643DB84AB0A04F4BCB4B5E92D6">
        <enum>(3)</enum>
        <text>Studies have found an increase in morbidity and mortality rates for individuals who suffer from
			 HHT.</text>
			</paragraph>
      <paragraph id="H55C8B25FBB7C46A1B5BC84F3A3FEAEDF">
        <enum>(4)</enum>
        <text>Due to the widespread lack of knowledge, accurate diagnosis, and appropriate intervention, 90
			 percent of HHT-affected families are at risk for preventable
			 life-threatening and disabling medical incidents such as stroke.</text>
			</paragraph>
      <paragraph id="HF5B4C76FA4184EB9BEA5171BB9851E2D">
        <enum>(5)</enum>
        <text>Early detection, screening, and treatment can prevent premature deaths, spontaneous hemorrhage,
			 hemorrhagic stroke, embolic stroke, brain abscess, and other long-term
			 health care complications resulting from HHT.</text>
			</paragraph>
      <paragraph id="HDB37DE2148A5419F8A278B4B7C921F1D">
        <enum>(6)</enum>
        <text>HHT is an important health condition with serious health consequences which are amenable to early
			 identification and diagnosis with suitable tests, and acceptable and
			 available treatments in established treatment centers.</text>
			</paragraph>
      <paragraph id="H463B6AC591F347A9BA25EC43CD0AEB89">
        <enum>(7)</enum>
        <text>Timely identification and management of HHT cases is an important public health objective because
			 it will save lives, prevent disability, and reduce direct and indirect
			 health care costs expenditures. A recent study has found use of a genetic
			 testing model for HHT diagnosis saves $9.9 million in that screening can
			 be limited to those persons within the family groups who actually have the
			 gene defect, leading to early intervention in those found to have
			 treatable AVMs.</text>
			</paragraph>
      <paragraph id="HC6A449391F174E588F847C6F6650EBDB">
        <enum>(8)</enum>
        <text>Without a new program for early detection, screening, and treatment, 14,000 children and adults who
			 suffer from HHT in the population today will suffer premature death and
			 disability.</text>
			</paragraph>
    </section>
    <section id="HF422576E9FCB48EB879FBA799C9DB694">
      <enum>3.</enum>
      <header>Purpose</header>
      <text display-inline="no-display-inline">The purpose of this Act is to create a federally led and financed initiative for early diagnosis
			 and appropriate treatment of hereditary hemorrhagic telangiectasia that
			 will result in the reduction of the suffering of families, prevent
			 premature death and disability, and lower health care costs through proven
			 treatment interventions.</text>
		</section>
    <section id="H32496CD71F584380A0D814C111B9B27D">
      <enum>4.</enum>
      <header>Centers for disease control and prevention</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/t:III/pt:B">Part B of title III of the Public Health Service Act</cato:entity-ref> is amended by inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/s:317T">section 317T</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/42/247b–22">42
			 U.S.C. 247b–22</cato:entity-ref>)</cato:entity> the following:</text>
			<quoted-block id="H341A309E1CDD4D5F8CFAF9706CCE4C74" style="OLC">
				<section id="H4DE8D58DAD2744BAA02BBB7E97CCC28D">
          <enum>317U.</enum>
          <header>Hereditary hemorrhagic telangiectasia</header>
					<subsection id="H9924418FDA3A488E8E7239CE0D292481">
            <enum>(a)</enum>
            <header>In general</header>
            <text>With respect to hereditary hemorrhagic telangiectasia (in this section referred to as <quote>HHT</quote>), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7523" entity-type="federal-body">Director of the Centers for Disease Control and Prevention</cato:entity-ref> (in this section referred to as
			 the <quote>Director</quote>) shall carry out the following activities:</text>
						<paragraph id="HEDDD7AACDD5C46E6AA428E187BF3A515">
              <enum>(1)</enum>
              <text>The conduct of population screening described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="HB729D85E6F7146F09CA11A4E640E0AF2">
              <enum>(2)</enum>
              <text>The identification and conduct of investigations to further develop and support guidelines for
			 diagnosis of, and intervention for, HHT, including cost-benefit studies.</text>
						</paragraph>
            <paragraph id="H3F636A85980146809A4F22505F43A80C">
              <enum>(3)</enum>
              <text>The development of a standardized survey and screening tool on family history.</text>
						</paragraph>
            <paragraph id="H511C042A9CC64FA29190F151428C602F">
              <enum>(4)</enum>
              <text>The establishment, in collaboration with a voluntary health organization representing HHT families,
			 of an HHT resource center within the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7523" entity-type="federal-body">Centers for Disease Control and
			 Prevention</cato:entity-ref> to provide comprehensive education on, and disseminate
			 information about, HHT to health professionals, patients, industry, and
			 the public.</text>
						</paragraph>
            <paragraph id="H47DF228DD3CB42C9A6CFBC4F4F6FF7F1">
              <enum>(5)</enum>
              <text>The conduct or support of public awareness programs in collaboration with medical, genetic, and
			 professional organizations to improve the education of health
			 professionals about HHT.</text>
						</paragraph>
          </subsection>
          <subsection id="HF32EB29B5A4548B49DE1BCFFAE36D98C">
            <enum>(b)</enum>
            <header>Collaborative approaches</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director</cato:entity-ref> shall carry out this section through collaborative approaches within the National
			 Center on Birth Defects and Developmental Disabilities and the Division
			 for Heart Disease and Stroke Prevention of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7523" entity-type="federal-body">Centers for Disease Control
			 and Prevention</cato:entity-ref> for clotting and bleeding disorders.</text>
					</subsection>
          <subsection id="H3F7D6222090841069B5C58FF3EB8088C">
            <enum>(c)</enum>
            <header>Population screening</header>
            <text>In carrying out population screening under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director</cato:entity-ref> shall—</text>
						<paragraph id="HA735EBA808EA40E296E303F54CCC7BA9">
              <enum>(1)</enum>
              <text>designate and provide funding for a sufficient number of HHT Treatment Centers of Excellence to
			 improve patient access to information, treatment, and care by HHT experts;</text>
						</paragraph>
            <paragraph id="H00354650F8AA4A938AA4AB15365DAE3D">
              <enum>(2)</enum>
              <text>conduct surveillance by means of a population study, supplemented by sentinel health care provider
			 or center surveillance, and by administrative database analyses as useful,
			 to accurately identify—</text>
							<subparagraph id="H9EAC75A5D7BF4703BCF653EA5ACA0446">
                <enum>(A)</enum>
                <text>the prevalence of HHT; and</text>
							</subparagraph>
              <subparagraph id="HF89EAFDDDB9148ACB271332C2A287EA0">
                <enum>(B)</enum>
                <text>the prevalence of hemorrhagic and embolic stroke, and brain abscess, resulting from HHT;</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H8A10411FC97A4E989AF67C125408BFBA">
              <enum>(3)</enum>
              <text>include HHT screening questions in the Behavioral Risk Factor Surveillance System survey conducted
			 by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7523" entity-type="federal-body">Centers for Disease Control and Prevention</cato:entity-ref> in order to screen a
			 broader population and more accurately determine the prevalence of HHT;</text>
						</paragraph>
            <paragraph id="H16EFE87744594C66BC5410D6EEDDA0BA">
              <enum>(4)</enum>
              <text>provide data collected under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c/p:2/sp:B" proposed="true">paragraph (2)(B)</cato:entity-ref> to the Paul Coverdell National Acute Stroke Registry
			 to facilitate—</text>
							<subparagraph id="H7F326CABA2434C13B8C9F9ACAA5E3EC2">
                <enum>(A)</enum>
                <text>analyses of the natural history of hemorrhagic and embolic stroke in HHT; and</text>
							</subparagraph>
              <subparagraph id="H7EBD761464B24F3AB88B515ECAC9220F">
                <enum>(B)</enum>
                <text>development of screening and artery-vein malformation treatment guidelines specific to prevention
			 of complications from HHT;</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H43B7AFEA6D8844F5930CE0564C309B23">
              <enum>(5)</enum>
              <text>develop and implement programs, targeted for physicians and health care professional groups likely
			 to be accessed by families with HHT, to increase HHT diagnosis and
			 treatment rates through the—</text>
							<subparagraph id="HD02CB191CEC742018E04087847D4736A">
                <enum>(A)</enum>
                <text>establishment of a partnership with HHT Treatment Centers of Excellence designated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c/p:1" proposed="true">paragraph
			 (1)</cato:entity-ref> through the creation of a database of patients assessed at such HHT
			 Treatment Centers of Excellence (including with respect to phenotype
			 information, genotype information, transfusion dependence, and
			 radiological findings);</text>
							</subparagraph>
              <subparagraph id="H49535F09D3084CC98B6BD2B6BED022D0">
                <enum>(B)</enum>
                <text>integration of such database with—</text>
								<clause id="HEB10976E381242729DFB8A5E61B0D5BA">
                  <enum>(i)</enum>
                  <text>the universal data collection system used by the Centers for monitoring hemophilia with the blood
			 disorders; and</text>
								</clause>
                <clause id="H67E2BC3A5D6247ABB06158F980FB0C41">
                  <enum>(ii)</enum>
                  <text>the Paul Coverdell National Acute Stroke Registry; and</text>
								</clause>
              </subparagraph>
              <subparagraph id="H2F82ABA0CE3C43F1AF721672C3CBA6FD">
                <enum>(C)</enum>
                <text>inclusion of other medical providers who treat HHT patients; and</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H6EDBB09E144245869E55D05C1305858C">
              <enum>(6)</enum>
              <text>use existing administrative databases on non-HHT Treatment Centers of Excellence patients—</text>
							<subparagraph id="H6F013FD0CA0041C0BD5D38E3AFF034A6">
                <enum>(A)</enum>
                <text>to learn about the natural history of HHT and the efficacy of various treatment modalities; and</text>
							</subparagraph>
              <subparagraph id="H597C26BD4BB246EBB3AC5D085D51BCA7">
                <enum>(B)</enum>
                <text>to better inform and develop screening and treatment guidelines associated with improvement in
			 health care outcomes, and research priorities relevant to HHT.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <subsection id="H80F55E8BB6B44AD7807E21D136646946">
            <enum>(d)</enum>
            <header>Eligibility for designation as an HHT treatment center of excellence</header>
            <text>In carrying out <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c/p:1" proposed="true">subsection (c)(1)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director</cato:entity-ref> may designate, as an HHT Treatment Center of
			 Excellence, academic health centers demonstrating each of the following:</text>
						<paragraph id="H92C1EA34814A4C5A82D51B503D729EBD">
              <enum>(1)</enum>
              <text>The academic health center possesses a team of medical experts capable of providing comprehensive
			 evaluation, treatment, and education to individuals with known or
			 suspected HHT and their health care providers.</text>
						</paragraph>
            <paragraph id="H3AEB9DA376D9465C8F3FB51C90AB7077">
              <enum>(2)</enum>
              <text>The academic health center has sufficient personnel with knowledge about HHT, or formal
			 collaboration with one or more partnering organizations for personnel or
			 resources, to be able to—</text>
							<subparagraph id="HBB218366EC1C49D68CFCDC5EB7215FA9">
                <enum>(A)</enum>
                <text>respond in a coordinated, multidisciplinary way to patient inquiries; and</text>
							</subparagraph>
              <subparagraph id="H886F6F2E44A54F968C30E27DB3B35436">
                <enum>(B)</enum>
                <text>coordinate evaluation, treatment, and education of patients and their families in a timely manner.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H64B3C5A4C16A43599F9605FDFFE7D6B2">
              <enum>(3)</enum>
              <text>The academic health center has the following personnel, facilities, and patient volume:</text>
							<subparagraph id="HB31DB0811E1E4B6BAECD33A61DD4AA31">
                <enum>(A)</enum>
                <text>A medical director with—</text>
								<clause id="HE298B8CAA8E14FF49E706A5EB5802BEB">
                  <enum>(i)</enum>
                  <text>specialized knowledge of the main organ manifestations of HHT; and</text>
								</clause>
                <clause id="HEFE70D93822546D4890538CD1D7AD1D5">
                  <enum>(ii)</enum>
                  <text>the ability to coordinate the multidisciplinary diagnosis and treatment of patients referred to the
			 center.</text>
								</clause>
              </subparagraph>
              <subparagraph id="HBC8EA27E05EC40A1B4924F39BD15CF53">
                <enum>(B)</enum>
                <text>Administrative staff with—</text>
								<clause id="H1F5D35C2DB2B495EB0FAFA34B5BC48AF">
                  <enum>(i)</enum>
                  <text>sufficient knowledge to respond to patient inquiries and coordinate patient care in a timely
			 fashion; and</text>
								</clause>
                <clause id="H8A4314C52D6843CBA5355E75645F2163">
                  <enum>(ii)</enum>
                  <text>adequate financial support to allow the staff to commit at least 25 to 50 percent of their time on
			 the job
			 to HHT.</text>
								</clause>
              </subparagraph>
              <subparagraph id="HC3192447C2984F08AB8AD1A3708A558C">
                <enum>(C)</enum>
                <text>An otolaryngologist with experience and expertise in the treatment of recurrent epistaxis in HHT
			 patients.</text>
							</subparagraph>
              <subparagraph id="H2C986887042B4617B061AEA6C37D0555">
                <enum>(D)</enum>
                <text>An interventional radiologist with experience and expertise in the treatment of pulmonary
			 arteriovenous malformations (AVM).</text>
							</subparagraph>
              <subparagraph id="HF5C9FEE3E2DC4268BBD64F0515F1AE01">
                <enum>(E)</enum>
                <text>A genetic counselor or geneticist with the expertise to provide HHT-specific genetic counseling to
			 patients and families.</text>
							</subparagraph>
              <subparagraph id="H80E4C665460A42AD8F6F1BD2AAF13B5E">
                <enum>(F)</enum>
                <text>On-site facilities to screen for all major organ manifestations of HHT.</text>
							</subparagraph>
              <subparagraph id="HEF6466340EDF43AC8EC5E844BB21FC1D">
                <enum>(G)</enum>
                <text>A patient volume of at least 25 new HHT patients per year.</text>
							</subparagraph>
              <subparagraph id="H8BF21345B10446859A7D41051DB45A9F">
                <enum>(H)</enum>
                <text>Established mechanisms to coordinate surveillance and outreach with HHT patient advocacy
			 organizations.</text>
              </subparagraph>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="HBBD102F8CD5540209CB07CD1D1AB862B">
      <enum>5.</enum>
      <header>Additional health and human services activities</header>
      <text display-inline="no-display-inline">With respect to hereditary hemorrhagic telangiectasia (in this section referred to as <quote>HHT</quote>), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7500" entity-type="federal-body">Secretary of Health and Human Services</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7530" entity-type="federal-body">Administrator of the Centers for
			 Medicare &amp; Medicaid Services</cato:entity-ref>, shall award grants on a competitive basis—</text>
			<paragraph id="H0FD2066BF7BB4342A497F78B45D7EBE3">
        <enum>(1)</enum>
        <text>for an analysis by grantees of the Medicare Provider Analysis and Review (MEDPAR) file to develop
			 preliminary estimates from the Medicare program under title XVIII of the
			 Social Security Act for preventable costs of annual health care
			 expenditures including items, services, and treatments associated with
			 untreated HHT furnished to individuals with HHT, as well as socioeconomic
			 costs such as disability expenditures associated with preventable medical
			 events in this population, who are entitled to benefits under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/t:XVIII/pt:A">part A of
			 title XVIII of the Social Security Act</cato:entity-ref> or enrolled under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/t:XVIII/pt:B">part B of such
			 title</cato:entity-ref>; and</text>
			</paragraph>
      <paragraph id="H72EE7D12F2B64456A9CC16E88BEC5DA4">
        <enum>(2)</enum>
        <text>to make recommendations regarding an enhanced data collection protocol to permit a more precise
			 determination of the total costs described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2014/s:5/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
			</paragraph>
    </section>
    <section id="H0D1C7DEA8FB645708ABD669D26B880BE">
      <enum>6.</enum>
      <header>National institutes of health</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:IV/pt:B">Part B of title IV of the Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/284">
          <cato:entity-ref entity-type="uscode" value="usc/42/284/etseq">42 U.S.C. 284 et seq.</cato:entity-ref>
        </external-xref>)</cato:entity> is amended by adding at
			 the end the following:</text>
			<quoted-block id="HEAF1EE1B69A24536AD7B0FB0492FC248" style="OLC">
				<section id="H35C57E302E334BD5BF1A578B5C07EA41">
          <enum>409K.</enum>
          <header>Hereditary hemorrhagic telangiectasia</header>
					<subsection id="H47A8ECA6B4C6444FAE3C32AF6FDF314C">
            <enum>(a)</enum>
            <header>HHT initiative</header>
						<paragraph id="H962F3F982939458DA4AD2CDD6B65573B">
              <enum>(1)</enum>
              <header>Establishment</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish and implement an HHT initiative to assist in coordinating activities
			 to improve early detection, screening, and treatment of people who suffer
			 from HHT. Such initiative shall focus on—</text>
							<subparagraph id="H6A2F22002371495696C6FA815514ABB2">
                <enum>(A)</enum>
                <text>advancing research on the causes, diagnosis, and treatment of HHT, including through the conduct or
			 support of such research; and</text>
							</subparagraph>
              <subparagraph id="H41FCA612569F4B8F8CA62D1E9A2068CF">
                <enum>(B)</enum>
                <text>increasing physician and public awareness of HHT.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HB5116379FB95464F807F4303D782E8F5">
              <enum>(2)</enum>
              <header>Consultation</header>
              <text>In carrying out this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consult with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">Director of the National
			 Institutes of Health</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7523" entity-type="federal-body">Director of the Centers for Disease Control
			 and Prevention</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection id="HACC23A6FD16C485D8AD0089942C9D126">
            <enum>(b)</enum>
            <header>HHT coordinating committee</header>
						<paragraph id="HD8909E38E820418BBAE42BFC5F35E364">
              <enum>(1)</enum>
              <header>Establishment</header>
              <text>Not later than 60 days after the date of the enactment of this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in
			 consultation with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">Director of the National Institutes of Health</cato:entity-ref>, shall
			 establish a committee to be known as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">HHT Coordinating Committee</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="HC64C43D348D445E386FC9B8ACA3A5ED2">
              <enum>(2)</enum>
              <header>Membership</header>
							<subparagraph id="H2D0127A9AEA045539E50E54E028797D8">
                <enum>(A)</enum>
                <header>In general</header>
                <text>The members of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">Committee</cato:entity-ref> shall be appointed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in consultation with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">Director
			 of the National Institutes of Health</cato:entity-ref>, and shall consist of 12 individuals
			 who are experts in HHT or arteriovenous malformation (AVM) as follows:</text>
								<clause id="HC118065C759D4B81AEE5548027D42181">
                  <enum>(i)</enum>
                  <text>Four representatives of HHT Treatment Centers of Excellence designated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c/p:1" proposed="true">section 317U(c)(1)</cato:entity-ref>.</text>
								</clause>
                <clause id="H1DC884DC47284948926EBA649E20723E">
                  <enum>(ii)</enum>
                  <text>Four experts in vascular, molecular, or basic science.</text>
								</clause>
                <clause id="H05E065C7705E4E429B997CCAB2856187">
                  <enum>(iii)</enum>
                  <text>Four representatives of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">National Institutes of Health</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
              <subparagraph id="H9AF8B69DBA4847FAA8CF4C522B39E02A">
                <enum>(B)</enum>
                <header>Chair</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall designate the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">Chair of the Committee</cato:entity-ref> from among its members.</text>
							</subparagraph>
              <subparagraph id="H48606B2EAEB8474296EC3FBAF6D7D41B">
                <enum>(C)</enum>
                <header>Interim members</header>
                <text>In place of the 4 members otherwise required to be appointed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:409K/ss:b/p:2/sp:A/cl:i" proposed="true">subparagraph (A)(i)</cato:entity-ref>, the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may appoint 4 experts in vascular, molecular, or basic science
			 to serve as members of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">Committee</cato:entity-ref> during the period preceding
			 designation and establishment of HHT Treatment Centers of Excellence under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U" proposed="true">section 317U</cato:entity-ref>.</text>
							</subparagraph>
              <subparagraph id="HDFA42E235BCF4D20B7EF5940C8696F28">
                <enum>(D)</enum>
                <header>Publication of names</header>
                <text>Not later than 30 days after the establishment of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">Committee</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish the
			 names of the Chair and members of the Committee on the Website of the
			 Department of Health and Human Services.</text>
							</subparagraph>
              <subparagraph id="HBE4A511B04DE405C920A764A45F0FD2C">
                <enum>(E)</enum>
                <header>Terms</header>
                <text>The members of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">Committee</cato:entity-ref> shall each be appointed for a 3-year term and, at the end of each such
			 term, may be reappointed.</text>
							</subparagraph>
              <subparagraph id="H9E07BC8CB6C04274A3F929AAF4FDDDEE">
                <enum>(F)</enum>
                <header>Vacancies</header>
                <text>A vacancy on the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">Committee</cato:entity-ref> shall be filled by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in the same manner in which the
			 original appointment was made.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H096A8FBDDE7747EEA735B1367B25431A">
              <enum>(3)</enum>
              <header>Responsibilities</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">Committee</cato:entity-ref> shall develop and coordinate implementation of a plan to advance research and
			 understanding of HHT by—</text>
							<subparagraph id="H3F3AE40632AF4DD8BCD38E7F29E0CC0B">
                <enum>(A)</enum>
                <text>conducting or supporting basic, translational, and clinical research on HHT across the relevant
			 national research institutes, national centers, and offices of the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">National Institutes of Health</cato:entity-ref>, including the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Heart, Lung, and Blood Institute" entity-parent-id="7529">National Heart, Lung, and
			 Blood Institute</cato:entity-ref>; the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">National Institute of Neurological Disorders and
			 Stroke</cato:entity-ref>; the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Institutes of Diabetes and Digestive and Kidney Diseases" entity-parent-id="7529">National Institutes of Diabetes and Digestive and Kidney
			 Diseases</cato:entity-ref>; the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Eunice Kennedy Shriver National Institute of Child Health and Human Development" entity-id="7529">Eunice Kennedy Shriver National Institute of Child Health
			 and Human Development</cato:entity-ref>; the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Cancer Institute" entity-parent-id="7529">National Cancer Institute</cato:entity-ref>; and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Office of Rare Diseases" entity-parent-id="7529">Office of
			 Rare Diseases</cato:entity-ref>; and</text>
							</subparagraph>
              <subparagraph id="HFEFB109877674CE0B9CC404B7CFBF84A">
                <enum>(B)</enum>
                <text>conducting evaluations and making recommendations to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">Director of the National
			 Institutes of Health</cato:entity-ref>, and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Cancer Institute" entity-parent-id="7529">Director of the National Cancer Institute</cato:entity-ref>
			 regarding the prioritization and award of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7529" entity-type="federal-body">National Institutes of Health</cato:entity-ref>
			 research grants relating to HHT, including with respect to grants for—</text>
								<clause id="HF8994087929D4284B9EBC260469A9EC2">
                  <enum>(i)</enum>
                  <text>expanding understanding of HHT through basic, translational, and clinical research on the cause,
			 diagnosis, prevention, control, and treatment of HHT;</text>
								</clause>
                <clause id="H33AFE355D8AF4A1A85359E9E580ABDDB">
                  <enum>(ii)</enum>
                  <text>training programs on HHT for scientists and health professionals; and</text>
								</clause>
                <clause id="HEFFE6F1691164D73818EF16D12F5D9FB">
                  <enum>(iii)</enum>
                  <text>HHT genetic testing research to improve the accuracy of genetic testing.</text>
								</clause>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="H7E3D47B5041447B39524799229019F1E">
            <enum>(c)</enum>
            <header>Definitions</header>
            <text>In this section:</text>
						<paragraph id="HE61E4B1E08B34052AA9E140DB2613CA4">
              <enum>(1)</enum>
              <text>The term <term>Committee</term> means the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">HHT Coordinating Committee</cato:entity-ref> established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:409K/ss:b" proposed="true">subsection (b)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="H99065DCE90614AE5AD34BC4C95FB505E">
              <enum>(2)</enum>
              <text>The term <term>HHT</term> means hereditary hemorrhagic telangiectasia.</text>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="HDAD2DFCB74E4471F907FDC689A7E457E">
      <enum>7.</enum>
      <header>Authorization of appropriations</header>
			<subsection id="H2BC98609732746D8A85532FE6CD40C46">
        <enum>(a)</enum>
        <header>In general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
            <cato:property name="purpose">To carry out <cato:entity-ref entity-type="act" value="Public Health Service Act/s:317U" proposed="true">section 317U of the Public Health Service Act</cato:entity-ref> as added by <cato:entity-ref entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2014/s:4" proposed="true">section 4 of this Act</cato:entity-ref>,
			 <cato:entity-ref entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2014/s:5" proposed="true">section 5 of this Act</cato:entity-ref>, and <cato:entity-ref entity-type="act" value="Public Health Service Act/s:409K" proposed="true">section 409K of the Public Health Service Act</cato:entity-ref>
			 as added by <cato:entity-ref entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2014/s:6" proposed="true">section 6 of this Act</cato:entity-ref>
            </cato:property>, there is authorized to be appropriated
			 <cato:funds-and-year amount="5000000" year="2015, 2016, 2017, 2018, 2019">$5,000,000 for each of fiscal years 2015 through 2019</cato:funds-and-year>.</cato:entity>
        </text>
			</subsection>
      <subsection id="H6DAC80E36D624AD48C68EBD7BC6BFF29">
        <enum>(b)</enum>
        <header>Resource center</header>
        <text>
          Of the amount authorized to be appropriated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2014/s:7/ss:a" proposed="true">subsection (a)</cato:entity-ref> for each of fiscal years 2015
			 through 2019, $1,000,000 shall be for carrying out <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:a/p:4" proposed="true">section 317U(a)(4) of
			 the Public Health Service Act</cato:entity-ref>, as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2014/s:4" proposed="true">section 4 of this Act</cato:entity-ref>
            .
        </text>
			</subsection>
      <subsection id="HB08B58A892B1492CB66FC055B3FA8F80">
        <enum>(c)</enum>
        <header>Offset</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">There is authorized to be appropriated to the <cato:entity-ref entity-id="7500" entity-type="federal-body">Department of Health and Human Services</cato:entity-ref> <cato:property name="purpose">for salaries
			 and expenses of the <cato:entity-ref entity-type="federal-body" entity-id="7500">Department</cato:entity-ref>
            </cato:property> <cato:funds-and-year amount="-5000000" year="2015, 2016, 2017, 2018, 2019">for each of fiscal years 2015 through 2019
			 the amount that is $5,000,000</cato:funds-and-year> less than the amount appropriated for such
			 salaries and expenses for fiscal year 2014.</cato:entity>
        </text>
			</subsection>
    </section>
  </legis-body>
</bill>
</doc>